Pneumonia News and Research

Latest Pneumonia News and Research

AiCuris’ AIC246 inhibitor treats patient with multi-organ HCMV disease

AiCuris announced today that its novel HCMV inhibitor AIC246 has been used successfully to treat a patient with multi-organ HCMV disease caused by multi-resistant virus. Details will be presented at the 48th IDSA meeting on October 23, presentation number LB-38.

22 Oct 2010

Zyvox achieves higher clinical success rate than vancomycin in MRSA nosocomial pneumonia study

Results of a new international phase 4 study of patients with nosocomial pneumonia due to proven methicillin-resistant Staphylococcus aureus (MRSA) demonstrated that the antibiotic Zyvox® (linezolid) achieved a statistically significantly higher clinical success rate compared with vancomycin for the primary endpoint. The ZEPHyR (Linezolid in the treatment of subjects with nosocomial pneumonia proven to be due to methicillin-resistant Staphylococcus aureus) study was the largest ever conducted in this population.

21 Oct 2010

ACS NSQIP recognizes Christiana Care Health System as participating hospital

The American College of Surgeons National Surgical Quality Improvement Program (ACS NSQIP) has recognized Christiana Care Health System as one of 26 ACS NSQIP participating hospitals in the United States that have achieved exemplary outcomes for surgical patient care.

20 Oct 2010

Smokers have more complications and higher death rate after surgery than non-smokers

Results from a clinical study presented at ANESTHESIOLOGY 2010 found that smokers have significantly more complications post-surgery than non-smokers, including a higher death rate.

20 Oct 2010

NIAID announces four new contracts for clinical trials to address problem of antimicrobial resistance

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, today announced four new contracts for large-scale clinical trials that address the problem of antimicrobial resistance.

20 Oct 2010

Hospital mortality rates decline by 7.98% from 2007 to 2009

A new independent study by HealthGrades of patient outcomes at America's hospitals found that patients at 5-star rated hospitals had a 72% lower risk of dying when compared with patients at 1-star-rated hospitals -- an enormous gap that has held steady over the past years even as overall mortality rates have improved.

20 Oct 2010

Forest Laboratories second quarter net sales increase 7.7% to $1,037.3 million

Forest Laboratories, Inc., an international pharmaceutical manufacturer and marketer, announced that diluted earnings per share equaled $1.00 in the second quarter of fiscal 2011.

19 Oct 2010

AHRQ analysis finds hospital charges for patient stay averaged $18,000 per day

Hospital charges for the most expensive patient stays at U.S. hospitals in 2008 averaged about $18,000 per day, according to the Agency for Healthcare Research and Quality. These patients were most likely to be in the hospital for treatment of septicemia, or blood infection, hardening of the arteries, and heart attacks.

19 Oct 2010

Researchers explore impact of various factors on increasing rates of Clostridium difficile infection

In five different studies presented at the American College of Gastroenterology's (ACG) 75th Annual Scientific meeting in San Antonio, researchers explored the impact of various factors on increasing rates of Clostridium difficile infection (C. difficile), such as the use of proton pump inhibitors (PPIs) and the substantial increase in antibiotic use due to new National Hospital Quality Measures; strategies to combat high rates of C. difficile infections; and cutting‐edge treatments for this potentially deadly-and quite common-infection.

19 Oct 2010

Federal court to allow Calif. case on Medicare underpayments to move forward; LA county gets new health department head

A recent court decision gave a group of California counties another chance to challenge what they contend are severe Medicare underpayments that jeopardize access to care across the country.

19 Oct 2010

Cempra to present data on solithromycin, TAKSTA at 48th Annual Meeting in Vancouver

Cempra Pharmaceuticals today announced poster presentations on its novel fluoroketolide antibiotic, solithromycin (CEM-101), and the Company's proprietary front-loading oral dosing regimen of sodium fusidate, TAKSTA (CEM-102) at the 48th Annual Meeting of the Infectious Diseases Society of America in Vancouver, British Columbia.

18 Oct 2010

Scientists to monitor effectiveness of Streptococcus vaccine

Respiratory infections and diarrhoeal diseases kill approximately four million children each year, with most deaths occurring in developing countries. New vaccines for Streptococcus pneumoniae, a bacterium that causes pneumonia, and rotavirus, the most common cause of severe diarrhoea, have proved successful in preventing the development of the diseases in clinical trials, but have yet to be used routinely in many parts of Africa.

15 Oct 2010

Research may pave way to cure cystic fibrosis

A University of Missouri researcher believes his latest work moves scientists closer to a cure for cystic fibrosis, one of the world's most common fatal genetic diseases.

13 Oct 2010

Ocular Therapeutix completes Proof of Principle clinical study with moxifloxacin punctum plug

Ocular Therapeutix, Inc. announced today the completion of a successful Proof of Principle clinical study with their novel sustained drug delivery moxifloxacin punctum plug.

13 Oct 2010

Alkermes' VIVITROL medication for treatment of opioid dependence

Alkermes, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved VIVITROL(naltrexone for extended-release injectable suspension) for the prevention of relapse to opioid dependence, following opioid detoxification.

13 Oct 2010

FDA approves Vivitrol for treatment of opioid-dependent patients

The U.S. Food and Drug Administration today approved Vivitrol to treat and prevent relapse after patients with opioid dependence have undergone detoxification treatment.

13 Oct 2010

Eli Lilly presents ALIMTA Phase III trial results at ESMO Annual Meeting

Eli Lilly and Company announced today that its global Phase III trial evaluating ALIMTA (pemetrexed for injection) in combination with cisplatin in patients with recurrent or metastatic squamous cell cancer of the head and neck (SCCHN) did not meet its primary endpoint for overall survival. Data were presented for the first time today at the 35th Annual Meeting of the European Society for Medical Oncology (ESMO).

11 Oct 2010

Afinitor-Sandostatin LAR Depot combination extends median PFS in patients with advanced carcinoid tumors

A Novartis Pharmaceuticals Corporation Phase III study of Afinitor® (everolimus) tablets in combination with Sandostatin® LAR Depot (octreotide acetate for injectable suspension) extended median progression-free survival (PFS), or time without tumor growth, in patients with advanced carcinoid tumors compared to taking octreotide LAR alone.

11 Oct 2010

Phase I study of Shigella dysenteriae bioconjugate vaccine meets primary, secondary endpoints

GlycoVaxyn AG, a leader in the development of innovative vaccines, announced today that the Phase I study of its Shigella dysenteriae bioconjugate vaccine has been completed and met the primary and secondary endpoints: demonstration of safety and immunogenicity.

8 Oct 2010

Scientists engineer bacterial cell wall with small molecules to combat diseases

A team of Yale University scientists has engineered the cell wall of the Staphylococcus aureus bacteria, tricking it into incorporating foreign small molecules and embedding them within the cell wall.

8 Oct 2010

Pneumonia News and Research

Latest Pneumonia News and Research

AiCuris’ AIC246 inhibitor treats patient with multi-organ HCMV disease

Zyvox achieves higher clinical success rate than vancomycin in MRSA nosocomial pneumonia study

ACS NSQIP recognizes Christiana Care Health System as participating hospital

Smokers have more complications and higher death rate after surgery than non-smokers

NIAID announces four new contracts for clinical trials to address problem of antimicrobial resistance

Hospital mortality rates decline by 7.98% from 2007 to 2009

Forest Laboratories second quarter net sales increase 7.7% to $1,037.3 million

AHRQ analysis finds hospital charges for patient stay averaged $18,000 per day

Researchers explore impact of various factors on increasing rates of Clostridium difficile infection

Federal court to allow Calif. case on Medicare underpayments to move forward; LA county gets new health department head

Cempra to present data on solithromycin, TAKSTA at 48th Annual Meeting in Vancouver

Scientists to monitor effectiveness of Streptococcus vaccine

Research may pave way to cure cystic fibrosis

Ocular Therapeutix completes Proof of Principle clinical study with moxifloxacin punctum plug

Alkermes' VIVITROL medication for treatment of opioid dependence

FDA approves Vivitrol for treatment of opioid-dependent patients

Eli Lilly presents ALIMTA Phase III trial results at ESMO Annual Meeting

Afinitor-Sandostatin LAR Depot combination extends median PFS in patients with advanced carcinoid tumors

Phase I study of Shigella dysenteriae bioconjugate vaccine meets primary, secondary endpoints

Scientists engineer bacterial cell wall with small molecules to combat diseases

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Evolving spectrophotometry for modern biopharma workflows

Pneumonia News and Research

Latest Pneumonia News and Research

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Evolving spectrophotometry for modern biopharma workflows

Newsletters you may be interested in